Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
The Ahmedabad based hospital in association with Sankalp India Foundation had established the BMT unit in 2017
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Nelarabine is in a class of medications called antimetabolites
The system is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes.
Subscribe To Our Newsletter & Stay Updated
